114 related articles for article (PubMed ID: 38911501)
1. Tuning Peptide-Based Nanofibers for Achieving Selective Doxorubicin Delivery in Triple-Negative Breast Cancer.
Bellavita R; Piccolo M; Leone L; Ferraro MG; Dardano P; De Stefano L; Nastri F; Irace C; Falanga A; Galdiero S
Int J Nanomedicine; 2024; 19():6057-6084. PubMed ID: 38911501
[TBL] [Abstract][Full Text] [Related]
2. Cell-Penetrating Doxorubicin Released from Elastin-Like Polypeptide Kills Doxorubicin-Resistant Cancer Cells in In Vitro Study.
Ryu JS; Kratz F; Raucher D
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33498762
[TBL] [Abstract][Full Text] [Related]
3. Doxorubicin-Loaded Micelle Targeting MUC1: A Potential Therapeutic for MUC1 Triple Negative Breast Cancer Treatment.
Khondee S; Chittasupho C; Tima S; Anuchapreeda S
Curr Drug Deliv; 2018; 15(3):406-416. PubMed ID: 28707580
[TBL] [Abstract][Full Text] [Related]
4. Cholecalciferol-PEG Conjugate Based Nanomicelles of Doxorubicin for Treatment of Triple-Negative Breast Cancer.
Kutlehria S; Behl G; Patel K; Doddapaneni R; Vhora I; Chowdhury N; Bagde A; Singh M
AAPS PharmSciTech; 2018 Feb; 19(2):792-802. PubMed ID: 29019073
[TBL] [Abstract][Full Text] [Related]
5. Enhanced Penetrability of a Tetrahedral Framework Nucleic Acid by Modification with iRGD for DOX-Targeted Delivery to Triple-Negative Breast Cancer.
Liu M; Ma W; Zhao D; Li J; Li Q; Liu Y; Hao L; Lin Y
ACS Appl Mater Interfaces; 2021 Jun; 13(22):25825-25835. PubMed ID: 34038071
[TBL] [Abstract][Full Text] [Related]
6. Design and Development of Polysaccharide-Doxorubicin-Peptide Bioconjugates for Dual Synergistic Effects of Integrin-Targeted and Cell-Penetrating Peptides for Cancer Chemotherapy.
Mansur AAP; Carvalho SM; Lobato ZIP; Leite MF; Cunha ADS; Mansur HS
Bioconjug Chem; 2018 Jun; 29(6):1973-2000. PubMed ID: 29790738
[TBL] [Abstract][Full Text] [Related]
7. A hyaluronic acid conjugate engineered to synergistically and sequentially deliver gemcitabine and doxorubicin to treat triple negative breast cancer.
Vogus DR; Evans MA; Pusuluri A; Barajas A; Zhang M; Krishnan V; Nowak M; Menegatti S; Helgeson ME; Squires TM; Mitragotri S
J Control Release; 2017 Dec; 267():191-202. PubMed ID: 28823957
[TBL] [Abstract][Full Text] [Related]
8. pH triggered re-assembly of nanosphere to nanofiber: The role of peptide conformational change for enhanced cancer therapy.
Liang P; Zheng J; Dai S; Wang J; Zhang Z; Kang T; Quan C
J Control Release; 2017 Aug; 260():22-31. PubMed ID: 28522193
[TBL] [Abstract][Full Text] [Related]
9. Intercellular adhesion molecule 1 antibody-mediated mesoporous drug delivery system for targeted treatment of triple-negative breast cancer.
Wang M; Liu W; Zhang Y; Dang M; Zhang Y; Tao J; Chen K; Peng X; Teng Z
J Colloid Interface Sci; 2019 Mar; 538():630-637. PubMed ID: 30554096
[TBL] [Abstract][Full Text] [Related]
10. Intracellularly Actuated Quantum Dot-Peptide-Doxorubicin Nanobioconjugates for Controlled Drug Delivery via the Endocytic Pathway.
Sangtani A; Petryayeva E; Wu M; Susumu K; Oh E; Huston AL; Lasarte-Aragones G; Medintz IL; Algar WR; Delehanty JB
Bioconjug Chem; 2018 Jan; 29(1):136-148. PubMed ID: 29191007
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapeutic Delivery from a Self-Assembling Peptide Nanofiber Hydrogel for the Management of Glioblastoma.
Karavasili C; Panteris E; Vizirianakis IS; Koutsopoulos S; Fatouros DG
Pharm Res; 2018 Jun; 35(8):166. PubMed ID: 29943122
[TBL] [Abstract][Full Text] [Related]
12. A chitosan-based cascade-responsive drug delivery system for triple-negative breast cancer therapy.
Niu S; Williams GR; Wu J; Wu J; Zhang X; Chen X; Li S; Jiao J; Zhu LM
J Nanobiotechnology; 2019 Sep; 17(1):95. PubMed ID: 31506085
[TBL] [Abstract][Full Text] [Related]
13. Peptide-Drug Conjugate Targeting Keratin 1 Inhibits Triple-Negative Breast Cancer in Mice.
Ziaei E; Paiva IM; Yao SJ; Sarrami N; Mehinrad P; Lai J; Lavasanifar A; Kaur K
Mol Pharm; 2023 Jul; 20(7):3570-3577. PubMed ID: 37307328
[TBL] [Abstract][Full Text] [Related]
14. Poly(ethylene glycol) shell-sheddable TAT-modified core cross-linked nano-micelles: TAT-enhanced cellular uptake and lysosomal pH-triggered doxorubicin release.
Zhang Y; Xiao Y; Huang Y; He Y; Xu Y; Lu W; Yu J
Colloids Surf B Biointerfaces; 2020 Apr; 188():110772. PubMed ID: 31999965
[TBL] [Abstract][Full Text] [Related]
15. Targeted delivery of Doxorubicin by folic acid-decorated dual functional nanocarrier.
Lu J; Zhao W; Huang Y; Liu H; Marquez R; Gibbs RB; Li J; Venkataramanan R; Xu L; Li S; Li S
Mol Pharm; 2014 Nov; 11(11):4164-78. PubMed ID: 25265550
[TBL] [Abstract][Full Text] [Related]
16. Characterization and Evaluation of Bone-Derived Nanoparticles as a Novel pH-Responsive Carrier for Delivery of Doxorubicin into Breast Cancer Cells.
Haque ST; Islam RA; Gan SH; Chowdhury EH
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32937817
[No Abstract] [Full Text] [Related]
17. Stepwise pH-responsive nanoparticles for enhanced cellular uptake and on-demand intracellular release of doxorubicin.
Chen WL; Li F; Tang Y; Yang SD; Li JZ; Yuan ZQ; Liu Y; Zhou XF; Liu C; Zhang XN
Int J Nanomedicine; 2017; 12():4241-4256. PubMed ID: 28652730
[TBL] [Abstract][Full Text] [Related]
18. Synergistic effect of photodynamic treatment and doxorubicin on triple negative breast cancer cells.
Yousefi Sadeghloo A; Khorsandi K; Kianmehr Z
Photochem Photobiol Sci; 2020 Nov; 19(11):1580-1589. PubMed ID: 33030191
[TBL] [Abstract][Full Text] [Related]
19. Peptide mediated active targeting and intelligent particle size reduction-mediated enhanced penetrating of fabricated nanoparticles for triple-negative breast cancer treatment.
Hu G; Chun X; Wang Y; He Q; Gao H
Oncotarget; 2015 Dec; 6(38):41258-74. PubMed ID: 26517810
[TBL] [Abstract][Full Text] [Related]
20. Glutamine-β-cyclodextrin for targeted doxorubicin delivery to triple-negative breast cancer tumors via the transporter ASCT2.
Zhou P; Liang X; Zhou C; Qin J; Hou C; Zhu Z; Zhang W; Wang S; Zhong D
J Mater Chem B; 2019 Sep; 7(35):5363-5375. PubMed ID: 31403158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
